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Abstract Animal models are widely used to study anti-
depressant-like effect in rodents. However, it should be
mentioned that pharmacological models do not always take
into account the complexity of the disease process. In the
present paper, we demonstrated that repeated but not acute
treatment with a low dose of reserpine (0.2 mg/kg i.p.) led to
a pharmacological model of depression which was based on
its inhibitory effect on the vesicular monoamine transporter
2, and monoamines depleting action in the brain. In fact, we
observed that chronic treatment with a low dose of reserpine
induced a distinct depressive-like behavior in the forced
swim test (FST), and additionally, it produced a significant
decrease in the level of dopamine, noradrenaline, and sero-
tonin in the brain structures. 1,2,3,4-Tetrahydroisoquinoline
(TIQ) and its close methyl derivative, 1-methyl-1,2,3,4-
tetrahydroisoquinoline (1MeTIQ) are exo/endogenous
amines present naturally in the mammalian brain which
demonstrated a significant antidepressant-like effect in the
FST and the reserpine model of depression in the rat. Both
compounds, TIQ and 1MeTIQ, administered chronically in
a dose of 25 mg/kg (i.p.) together with reserpine completely
antagonized reserpine-produced depression as assessed by
the immobility time and swimming time. Biochemical data
were in agreement with behavioral experiments and dem-
onstrated that chronic treatment with a low dose of reserpine
in contrast to acute administration produced a significant
depression of monoamines in the brain structures and
impaired their metabolism. These neurochemical effects
obtained after repeated reserpine (0.2 mg/kg i.p.) in the
brain structures were completely antagonized by joint TIQ
or 1MeTIQ (25 mg/kg i.p.) administration with chronic
reserpine. A possible molecular mechanism of action of TIQ
and 1MeTIQ responsible for their antidepressant action is
discussed. On the basis of the presented behavioral and
biochemical studies, we suggest that both compounds may
be effective for the therapy of depression in clinic as new
antidepressants which, when administered peripherally
easily penetrate the blood–brain barrier, and as endogenous
compounds may not have adverse side effects.
Keywords Depression-reserpine model  Forced swim
test  Tetrahydroisoquinolines  Monoamines metabolism 
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Introduction
In recent years, depression has been recognized as a major
public health problem. Understanding how to prevent and
treat depression is therefore, an urgent subject. It is well
known that monoamine neurotransmitters, such as dopa-
mine (DA), noradrenaline (NA), and serotonin (5-HT) in
the central nervous system play a key role in the patho-
physiology of depression (Cantello et al. 1989 Chan-Palay
and Asan 1989; Colpaert 1987; Mayeux et al. 1984; El-
hwuegi 2004). However, abnormalities in monoaminergic
neurotransmission are associated with a number of neuro-
logical disorders including Parkinson’s disease (PD) and
schizophrenia. Although the mechanism provoking
depression has not been clearly elucidated; however, oxi-
dative stress associated with generation of reactive oxygen
species (ROS) can be one of the main causes in molecular
processes underlying this disease. The endogenous gener-
ation of ROS results from metabolism of monoamines in
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the cytosol and auto-oxidation of monoamines. Physio-
logically, neurons have many endogenous mechanisms to
maintain health and protect against degeneration. The
vesicular monoamine transporter 2 (VMAT2) is one of
such custodians that function to regulate the cytosolic
environment of neurons, protecting them from endogenous
and exogenous toxins (Uhl 1998; Miller et al. 1999).
Localized on vesicular membranes in neurons, VMAT2
acts to accumulate cytosolic monoamines in synaptic ves-
icles after they have been synthesized from their precursors
for regulated exocytotic release as well as after their re-
uptake from the synaptic cleft into the neuron (Surratt et al.
1993). The monoamines, particularly DA and NA have the
ability to undergo spontaneous oxidation in the cytosol,
which is potentially damaging to cellular structures (Gra-
ham 1978; Antkiewicz-Michaluk et al. 2006; Wa˛sik et al.
2009). Thus, the level of VMAT2 expression plays an
important role in nerve cell safety and is essential for
cellular susceptibility to oxidation (Liu et al. 1992). In fact,
in VMAT2-deficient mice the striatal DA level was
reduced by 85 % with a concomitant reduction in the
metabolites, DOPAC and HVA. In addition, several
markers of oxidative stress and damage were observed in
the VMAT2-deficient mice. Moreover, it was found that
disruption of VMAT2 led to depressive-like phenotypes
(Ziemssen and Reichmann 2007; Taylor et al. 2009).
Reserpine is a vesicular monoamine re-uptake blocker,
which depletes monoamines in the brain, and produces
depression-like syndrome in animals (Kandel 2000; Na-
gakura et al. 2009; Rojas-Corrales et al. 2004). Thus, it
seems to be an ideal model to screen the potential antide-
pressants. In the present study, we analyzed the antide-
pressant potential of endogenous substances from the
tetrahydroisoquinoline group: 1,2,3,4-tetrahydroisoquino-
line (TIQ) and its close methyl-derivative, 1-methyl-
1,2,3,4-tetrahydroisoquinoline (1MeTIQ; Fig. 1). Both
these compounds are members of the TIQ family wide-
spread in plant, animal, and human brains (McNaught et al.
1998; Rommelspacher and Susilo 1985). Among several
endogenous TIQs, 1MeTIQ has a special position as a
neuroprotective compound with antiparkinsonian potential,
since it was demonstrated to reverse bradykinesia induced
by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
or 1-benzyl-1,2,3,4-tetrahydroisoquinoline (1BnTIQ)
(Makino et al. 1990; Kotake et al. 1995; Tasaki et al. 1991).
Both TIQ and 1MeTIQ, in contrast to other TIQs (e.g.,
1BnTIQ and salsolinol), inhibited MAO A and B activities
in the micro-molar concentrations (Patsenka and Ant-
kiewicz-Michaluk 2004). The compounds had antioxidant
properties as indicated by the ability of TIQ and 1MeTIQ
to inhibit free radical formation and to abolish H2O2 gen-
eration from DA via the Fenton reaction (for review see
Singer and Ramsay 1995; Antkiewicz-Michaluk et al.
2006). Those results demonstrate that TIQ and 1MeTIQ are
MAO inhibitors and possess intrinsic antioxidant proper-
ties. In that light of these observations the question arises
whether TIQ and 1MeTIQ may have antidepressant effect?
Both compounds easily penetrate into the brain through the
blood–brain barrier, and their neuroprotective properties
might be relevant from the clinical point of view. Addi-
tionally, these compounds have not been investigated yet,
in the context of their antidepressant properties in the
reserpine model of depression.
In the present paper, we examined behavioral and neu-
rochemical effects of acute and repeated treatment with a
low dose of reserpine, and then we evaluated antidepres-
sant-like effect of the investigated compounds, TIQ and
1MeTIQ, in reserpinized rats as a model of depression.
We used the behavioral forced swim test (FST) to
examine the antidepressant properties of TIQ and 1MeTIQ.
The FST is a test with high predictive validity for antide-
pressant efficacy in human depression. Recently, a behav-
ior sampling technique was developed that scores
individual response categories, including immobility,
swimming, and climbing (Detke et al. 1995). Although all
antidepressant drugs reduce immobility time in the FST, at
least two distinct active behavioral patterns are produced
by pharmacologically selective antidepressant drugs (Bor-
sini and Meli 1988). Serotonin-selective re-uptake inhibi-
tors increase swimming behavior, while drugs acting
primarily to elevate extracellular levels of NA or DA
increase climbing behavior (Borsini 1995; Detke et al.
1995; Detke and Lucki 1996). Additionally, the locomotor
activity test was used to check motor function of reserpi-
nized rats.
In the second part of the study, in addition to the
behavioral tests, we carried out also the neurochemical
ex vivo studies in the rat brain structures [ventral tegmental
area (VTA), nucleus accumbens, and hypothalamus] to
determine: the levels of monoamines and their metabolites,







Fig. 1 Chemical structure of
TIQ and its close derivative,
1MeTIQ




Behavioral tests were carried out on male Wistar rats
(Charles River) of initial body weight 230–240 g (about
7 weeks old). The animals were kept under standard lab-
oratory conditions with free access to laboratory food and
tap water, at room temperature of 22 C with an artificial
day-night cycle (12/12 h, light on at 7 a.m.). All the pro-
cedures were carried out in accordance with the National
Institutes of Health Guide for the Care and Use of Labo-
ratory Animals and were granted an approval from the
Bioethics Commission as compliant with Polish Law. The
experimental protocols were approved by the Local Bio-
ethics Commission of the Institute of Pharmacology, Polish
Academy of Sciences in Krako´w.
Drugs
1,2,3,4-Tetrahydroisoquinoline hydrochloride (TIQ, Sigma-
Aldrich, USA); 1MeTIQ were synthesized in Department of
Drug Chemistry, Institute of Pharmacology Polish Academy
of Sciences, Krakow, Poland), and the purity of the com-
pound was verified by measurement of the melting point, and
homogeneity was assessed on a chromatographic column.
TIQ and 1MeTIQ were dissolved in sterile 0.9 % NaCl
solution. The chemical structures of TIQ and 1MeTIQ are
shown in Fig. 1. Reserpine (Sigma-Aldrich, USA) was sus-
pended in 1 % Tween 80. The drugs were injected in a vol-
ume of 4 ml/kg.
Treatments
In order to check pro-depressive effect of reserpine, the
experimental protocol was divided into two main parts. In
the first part of the study (reserpine model of depression),
we analyzed reserpine-induced depressive disorder after a
single and repeated administration (once daily for 14 days)
of reserpine (0.2 mg/kg i.p.) in a variety of behavioral
(forced swimming test, locomotor activity: travelled dis-
tance and rearing times), and biochemical tests (the con-
centration of monoamines: DA, NA, and serotonin in the
brain structures). In order to evaluate the duration of the
obtained reserpine effect, the tests were carried out
120 min after the last injection.
In the second part of that study, we evaluated the anti-
depressant-like effect of the investigated TIQs. For this
purpose, TIQ and 1MeTIQ in a dose of 25 mg/kg i.p. were
administered chronically (14 days) 30 min before each
reserpine injection (0.2 mg/kg i.p.), and their effects on the
reserpine-induced depressive-like disorder was investigated
in the behavioral and biochemical tests 120 min after the last
dose of reserpine. Control group received chronically 1 %
Tween 80. Immediately after the end of behavioral tests, the
rats were killed by decapitation, and different brain struc-
tures (VTA; nucleus accumbens and hypothalamus) were
dissected for the later neurochemical studies that assessed
the metabolism of monoamines by high pressure chroma-
tography method (HPLC) with electrochemical detection
(ED). The experiments were carried out between 10 a.m. and
4 p.m. Each experimental group consisted of 6-8 rats.
Behavioral Studies
The FST Procedure
The studies were carried out on rats and were based on the
method of Porsolt et al. (1978). All the animals were
individually tested in the FST on two consecutive days
with one session per day. On the first day, the rats were
individually placed in non-transparent plastic cylinders
(diameter: 23 cm, height: 50 cm) containing 30 cm of
water, maintained at 25–26 C. They were let to swim for
15 min before being removed (pre-test session). After that
the animals were dried and returned to their home cages.
The procedure was repeated 24 h later, and the time of the
escape-oriented behavior of the rats was recorded (for
5-min test session). The observed behavioral parameters (in
the order of priority) were: time spent floating in water
(immobility), swimming, and struggling (climbing).
According to Detke et al. (1995), the immobility is
described as behavior of the rat when it makes only the
movements necessary to keep its head above the water. In
this case, animals can make certain, slight swimming
movements in order to remain afloat. Climbing is defined
as vigorous movements of four limbs, with the front paws
breaking against the wall of the cylinder. During swimming
rats make coordinated and sustained movements (more
than necessary) with all four limbs, usually traveling
around the interior of the cylinder, but without breaking the
surface of the water with forelimbs. Water was changed
between subjects. The FST was performed 120 min after
acute and chronic (14 days) administration of reserpine
(0.2 mg/kg i.p.) In combined treatment groups, TIQ and
1MeTIQ (25 mg/kg i.p.) were administered chronically
30 min before each dose of reserpine.
Locomotor Activity
The locomotor activity was measured in actometers (Opto-
Varimex activity monitors, Columbus Instruments, USA)
linked on-line to an IBM-PC compatible computer. Each
cage (43 x 44 x 25 cm) was surrounded with a 15 9 15
array of photocell beams located 3 cm from the floor sur-
face. Interruptions of these photocell beams were counted
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as a measure of horizontal and vertical locomotor activity.
Horizontal locomotor activity was defined as the travelled
distance (in cm), and the vertical activity as rearing times
(in seconds). Locomotor activity was analyzed using Auto-
Track Software Program (Columbus Instruments, USA)
and recorded in 15 min intervals for 60 min. Locomotor
activity was measured at 120 min after acute and chronic
administration (14 days) of reserpine (0.2 mg/kg i.p.).
Neurochemical Studies
Ex Vivo: Monoamine Metabolism in Rat Brain Structures
The animals were killed by decapitation after the end of
behavioral experiments. The brains were rapidly removed
and dissected on an ice-cold glass plate. After decapitation,
the VTA, nucleus accumbens, and hypothalamus were taken
and immediately frozen on solid CO2 (-70 C) until used
for biochemical assays. DA and its metabolites, the intran-
euronal, 3,4-dihydroxyphenylacetic acid (DOPAC); the
extraneuronal, 3-methoxytyramine (3-MT), and the final
metabolite, homovanillic acid (HVA); NA and its main
extraneuronal brain metabolite, normetanephrine, (NM) and
serotonin (5-HT) and its intraneuronal metabolite 5-hy-
droxyindolacetic acid (5-HIAA) were assayed by means of
high-performance liquid chromatography (HPLC) with
electrochemical detection (ED). The tissue samples were
weighted and homogenized in ice-cold 0.1 M trichloroacetic
acid containing 0.05 mM ascorbic acid. After centrifugation
(10,0009g, 5 min), the supernatants were filtered through
RC58 0.2 lm cellulose membranes (Bioanalytical Systems,
West Lafayette, IN, USA). The chromatograph HP 1050
(Hewlett-Packard, Golden, CO, USA) was equipped with
Hypersil columns BDS-C18 (4 9 100 mm, 3 lm). The
mobile phase consisted of 0.05 M citrate–phosphate buffer,
pH 3.5; 0.1 mM EDTA; 1 mM sodium octyl sulfonate; and
3.5 % methanol. The flow rate was maintained at 1 ml/min.
DA, serotonin, NA, and their metabolites were quantified by
peak area comparisons with standards run on the day of
analysis (ChemStation, Hewlett-Packard software computer
program).
Calculations and Statistics
The data of behavioral and neurochemical studies were
calculated by means of a one-way or two-way analysis of
variance (ANOVA), followed when appropriate by Dun-
can’s post hoc test. The data were considered statistically
significant when P \ 0.05.
The total catabolism rate for DA was assessed from the
ratio of the final DA metabolite concentration, HVA to DA
concentration and expressed as the catabolic rate index
[HVA]/[DA] 9 100; the rate of DA MAO-dependent
oxidation as the ratio: [DOPAC]/[DA] 9 100; the rate of
DA COMT-dependent O-methylation as the ratio: [3-MT]/
[DA] 9 100. Analogously, the rate of NA metabolism was
expressed as the ratio of the extraneuronal metabolite
normetanephrine to NA: [NM]/[NA] 9 100 and serotonin
as the ratio: [5-HIAA]/[5-HT] 9 100. The indices were
calculated using concentrations from individual tissue
samples (Antkiewicz-Michaluk et al. 2001).
Results
Behavioral Studies
The Effect of Acute and Chronic Administration
of Reserpine on the FST Carried out 120 min After the Last
Injection
Chronic but not acute administration of reserpine (0.2 mg/
kg i.p.) produced pro-depressive activity and significantly
increased the immobility time in the FST in rats
F2,18 = 2.66; P \ 0.05 (Fig. 2a). The one-way ANOVA
showed a significant decrease (*25 %) in the swimming
activity after chronic reserpine F2,18 = 2.69; P \ 0.05 and
no change in the climbing (Fig. 2b, c).
The Locomotor Activity Test
Both acute and chronic administration of reserpine in a low
dose (0.2 mg/kg i.p.) produced a significant decrease in the
horizontal (travelled distance in cm) and vertical (rearing
time in seconds) exploratory locomotor activity of rats
(P \ 0.001) during the first 30 min after the start of the
measurement of motor activity. At later intervals of 45 and
60 min, no changes in motor activity were detected
between reserpine groups and the control (Fig. 3a, b).
The Effect of Chronic Administration TIQ and 1MeTIQ
on Reserpine-Evoked Depressive-like Behavior in the FST
in the Rat
Chronic administration (14 days) of TIQ and 1MeTIQ in a
dose of 25 mg/kg i.p. together with reserpine (0.2 mg/kg
i.p.) produced antidepressant-like activity and completely
antagonized pro-depressive effect of chronic reserpine
(Fig. 4a, b). The one-way ANOVA showed a significant
effect of treatments, F3,21 = 9.75; P \ 0.0003, and Dun-
can’s post hoc test revealed an increase in the immobility
time for reserpine alone versus control group (P \ 0.05),
and its significant decrease in both the combined groups:
TIQ ? reserpine (P \ 0.01) and 1MeTIQ ? reserpine
(P \ 0.05) (Fig. 4a). Similarly, a significant decrease in the
swimming time in reserpine group was completely
88 Neurotox Res (2014) 26:85–98
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antagonized by TIQ and 1MeTIQ in the combined treatment
groups, F3,21 = 4.47; P \ 0.01 (Fig. 4b). The climbing time
was significantly increased only in the combined treatment
group 1MeTIQ ? reserpine, F3,21 = 3.28; P \ 0.05
(Fig. 4c).
Neurochemical Studies
The Comparison of a Single and Repeated Administration
of a Low Dose of Reserpine on the Concentration
of Monoamines: DA, NA, and Serotonin in the Nucleus
Accumbens and Hypothalamus
The one-way ANOVA showed a significant effect of chronic
reserpine administration on DA F2/15 = 6.81, P \ 0.002
and NA level F2/15 = 3.39, P \ 0.03 in the nucleus ac-
cumbens. The Duncan’s post hoc test indicated that chronic
treatment with reserpine in contrast to a single injection
decreased significantly the level of DA (by *35 % vs.
control; P \ 0.01) and NA (about 50 % of control;
P \ 0.05). Additionally, the one-way ANOVA demon-
strated also a significant effect of chronic reserpine on DA
F2/15 = 3.83, P \ 0.02; NA F2/15 = 26.94, P \ 0.0001;
serotonin F2/15 = 16.85, P \ 0.0007 concentrations in the
hypothalamus. The Duncan’s post hoc test revealed a sig-
nificant decrease in all monoamines: DA (about 40 % of
control, P \ 0.05); NA (30 % of control, P \ 0.02) and
serotonin (about 35 % of control, P \ 0.01) after chronic
reserpine and no effect of a single injection (Table 1).
The Effect of Chronic Administration of TIQ and 1MeTIQ
on Reserpine-Induced Changes in the DA System
Dopamine The one-way ANOVA indicated a significant
effect of treatment on DA concentration in all investigated
structures: VTA (F3/20 = 3.68; P\ 0.05), nucleus accum-
bens (F3/20 = 4.10; P\0.02) and hypothalamus (F3/20 =














































Fig. 2 The effect of acute and
repeated administration with a
low dose of reserpine on FST in
rat. Reserpine (0.2 mg/kg i.p.)
was administered acute or
chronically, once daily for
14 days. Control group received
chronically 1 % Tween 80. FST
was carried out 120 min after
the last dose of reserpine. The
data are the mean ± SEM. The
results were analyzed by means
of one-way ANOVA, followed
when appropriate, by post hoc
Duncan’s test. Statistical
significance: *P \ 0.05 versus
control group
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significant decrease in DA concentration (from 20 to 40 % of
control) in all investigated structures after chronic reserpine
administration. The Duncan’s post hoc test demonstrated that
TIQ and 1MeTIQ completely antagonized the reserpine-
induced decrease in the DA concentration, and the level of
DA returned to the control value in the combined treatment
groups (Table 2).
Dihydroxyphenylacetic Acid The one-way ANOVA
demonstrated a significant effect of treatment on DOPAC
level in the VTA (F3/20 = 12.30; P \ 0.00008), nucleus
accumbens (F3/20 = 18.77; P \ 0.00005), and hypothala-
mus (F3/20 = 14.37; P \ 0.00003). The Duncan’s post hoc
test indicated that TIQ and 1MeTIQ administered together
with reserpine significantly (P \ 0.01) decrease the
DOPAC concentration versus control group in all investi-
gated structures (Table 2).
3-Methoxytyramine The one-way ANOVA revealed a
significant effect of treatment on 3-MT concentration in the
VTA (F3/20 = 7.83; P\0.001), and hypothalamus (F3/20 =
4.41; P\0.01) but not in the nucleus accumbens (F3/20 =
1.06; NS). The Duncan’s post hoc test demonstrated that
TIQ and 1MeTIQ administered together with reserpine
produced the significant increase in 3-MT concentration
versus control group in the VTA and hypothalamus (from
50 % up to 100 % of control, respectively) (Table 2).
Homovanillic Acid The statistical analysis revealed a
significant effect of treatment on the level of HVA in the
VTA (F3/20 = 13.39; P \ 0.00005), nucleus accumbens
(F3/20 = 13.00; P \ 0.00006), and hypothalamus (F3/20 =
7.83; P \ 0.001). The Duncan’s post hoc test demonstrated
that HVA level was significantly decreased (P \ 0.01) by
reserpine (only in the nucleus accumbens) and by TIQ and
1MeTIQ in the combined groups in the investigated
structures (Table 2).
The Indices of DA Catabolism The one-way ANOVA
indicated a significant effect of treatment on the rate of
total DA catabolism [HVA]/[DA] in the investigated
structures: VTA (F3/20 = 8.19; P \ 0.0009), nucleus ac-
cumbens (F3/20 = 17.51; P \ 0.00008), and hypothalamus
(F3/20 = 9.02; P \ 0.0005) (Table 3). The Duncan’s post
hoc test demonstrated the opposite effect of reserpine on
the total DA catabolism: in the nucleus accumbens, it
significantly decreased (about 25 % of control; P \ 0.01),
while in the hypothalamus, it significantly increased (about
50 % of control; P \ 0.01), and there was no change in the
VTA. An increase in the rate of total DA catabolism after
reserpine in the hypothalamus was completely antagonized
by TIQ and 1MeTIQ (Table 3).
At the same time, the statistical analysis demonstrated a
significant increase in the rate of DA oxidation, [DOPAC]/
[DA] after chronic reserpine in all tested structures: VTA (F3/20 =
71.89; P \ 0.00000), nucleus accumbens (F3/20 = 34.88;
P \ 0.00000) and hypothalamus (F3/20 = 53.42; P \
0.00000), total antagonism of this effect by TIQ, and 1MeTIQ
in the combined groups (Table 3).
The rate of DA O-methylation, [3-MT]/[DA] was signifi-
cantly elevated only by TIQ and 1MeTIQ in the combined
treatment groups: in the VTA (F3/20 = 14.54; P \ 0.0002)
and in the hypothalamus (F3/20 = 6.56; P \ 0.002).
The Effect of Chronic Administration of TIQ and 1MeTIQ
on Reserpine-Induced Changes in the Noradrenergic
System
Noradrenaline The one-way ANOVA revealed a signifi-
cant effect of treatment on NA concentration in the all
investigated structures: VTA (F3/20 = 4.35; P \ 0.01),
nucleus accumbens (F3/20 = 3.39; P \ 0.03), and hypo-
thalamus (F3/20 = 3.62; P \ 0.05). The Duncan’s post hoc
test indicated a significant decrease in NA in the nucleus
accumbens (about 45 % of control; P \ 0.05) and in the
hypothalamus (about 25 % of control; P \ 0.05). TIQ and









































Fig. 3 The effect of acute and repeated administration with a low
dose of reserpine on the horizontal and vertical motor activity in rat.
Reserpine (0.2 mg/kg i.p.) was administered acute or chronically,
once daily for 14 days. Control group received chronically 1 %
Tween 80. Horizontal locomotor activity was defined as the travelled
distance (in cm) and the vertical activity as rearing times (in seconds).
Locomotor activity was analyzed 120 min after acute and chronic
treatment of reserpine (0.2 mg/kg i.p.) during 60 min using Auto-
Track Software Program. The data are the mean ± SEM. The number
of animals per group, N = 6–8. The results were analyzed by means
of one-way ANOVA, followed when appropriate, by post hoc
Duncan’s test. Statistical significance: **P \ 0.001 versus control
group
90 Neurotox Res (2014) 26:85–98
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antagonized the reserpine-induced depression in the con-
centration of NA (Table 4).
Normetanephrine The one-way ANOVA demonstrated a
significant effect of treatment on NM level in the VTA
(F3/20 = 3.65; P \ 0.03) and hypothalamus (F3/20 =
33.32; P \ 0.00000). The Duncan’s post hoc test indicated
that reserpine led to a decrease in NM level in the brain
structures, and TIQ and 1MeTIQ administered together
with reserpine significantly antagonized this effect. Par-
ticularly in the hypothalamus, TIQ led to a strong increase
(about 400 % of control group, P \ 0.001) substantially
exceeding the value of NM in the control group (Table 4).
The Index of NA Catabolism: [NM]/[NA] The one-way
ANOVA revealed a significant effect of treatment on the
index of NA catabolism [NM]/[NA] only in the hypothalamus
(F3/20 = 40.13; P \ 0.00000). The Duncan’s post hoc test
indicated that TIQ and 1MeTIQ in the combined groups
strongly increased the index of NA catabolism (about 600 %,
P \ 0.001; and 300 %, P \ 0.001; respectively) (Table 4).
The Effect of Chronic Administration of TIQ and 1MeTIQ
on Reserpine-Induced Changes in the Serotonin System
Serotonin The one-way ANOVA indicated a significant
effect of treatment on the level of serotonin only in the
hypothalamus (F3/20 = 6.95; P \ 0.002). The Duncan’s
post hoc test indicated that chronic administration of reser-
pine produced a significant decrease in serotonin concen-
tration in the VTA (about 35 % of control, P \ 0.05) and in
the hypothalamus (about 30 % of control, P \ 0.01). These
effects were antagonized by TIQ and 1MeTIQ in the com-



















































Fig. 4 The effect of chronic
administration TIQ and
1MeTIQ (25 mg/kg i.p.) on
reserpine (0.2 mg/kg i.p.)
evoked depressive-like effect in
FST in rat. Reserpine (0.2 mg/
kg i.p.) was administered
chronically, once daily for
14 days. TIQ and 1MeTIQ
(25 mg/kg i.p.) were
administered 30 min before
each dose of reserpine
(combined groups). Control
group received chronically 1 %
Tween 80. FST was carried out
120 min after the last dose of
reserpine. The data are the
mean ± SEM. The results were
analyzed by means of one-way
ANOVA, followed when
appropriate, by post hoc
Duncan’s test. Statistical
significance: *P \ 0.05,
**P \ 0.01 versus control
group. ?P \ 0.05, ??P \ 0.01
versus reserpine group
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Table 1 The comparison of a single and repeated administration of a low dose of reserpine on the concentration of monoamines: DA, NA, and
serotonin in rat brain structures
Treatment (mg/kg) N DA (ng/g wt) NA (ng/g wt) Serotonin (ng/g wt)
Nucleus accumbens
Control 6 9,601 ± 502 134 ± 11 419 ± 41
Reserpine acute 6 8,870 ± 388 102 ± 16 320 ± 27
Reserpine chronic 6 7,075 ± 445**? 76 ± 9* 359 ± 26
F F(2/15) = 6.81 F(2/15) = 3.39 F(2/15) = 1.83
P \ 0.002 P \ 0.03 NS
Hypothalamus
Control 6 511 ± 49 1,901 ± 70 796 ± 19
Reserpine acute 6 417 ± 28 1,806 ± 77 754 ± 27
Reserpine chronic 6 294 ± 77* 1,323 ± 46**?? 509 ± 24**??
F F(2/15) = 3.73 F(2/15) = 26.94 F(2/15) = 16.85
P \ 0.02 P \ 0.0000001 P \ 0.000007
Reserpine (0.2 mg/kg i.p.) was administered once (acute treatment) and for 14 days once daily (chronic treatment). Control group received once
daily for 14 days 1 % Tween 80. Animals were decapitated 120 min after the last injection of reserpine (acute and chronic treatment). The
concentration (ng/g wet tissue) of monoamines: DA, NA, and serotonin was measured in the rat nucleus accumbens and hypothalamus. The data
are the mean ± SEM. The results were analyzed by means of one-way ANOVA, followed when appropriate, by post hoc Duncan’s test
Statistical significance: * P \ 0.05, ** P \ 0.01 versus control group; ? P \ 0.05, ?? P \ 0.01 versus reserpine acute
Table 2 The effect of chronic administration of TIQ and 1MeTIQ on reserpine-induced changes in the level of DA and its metabolites in rat
brain structures
Chronic treatment (mg/kg) N DA (ng/g wt) DOPAC (ng/g wt) 3-MT (ng/g wt) HVA (ng/g wt)
VTA
Control 6 1,990 ± 269 594 ± 67 39 ± 8.7 362 ± 16
Reserpine 0.2 6 1,643 ± 70* 593 ± 36 40 ± 3.1 343 ± 22
Reserpine 0.2 ? TIQ25 6 2,077 ± 1391 342 ± 24**?? 79 ± 5.6*? 286 ± 15**?
Reserpine 0.2 ? 1MeTIQ25 6 2,255 ± 1501 299 ± 42**?? 94 ± 16.9**?? 216 ± 17**??
F F(3/20) = 3.66 F(3/20) = 12.30 F(3/20) = 7.83 F(3/20) = 13.39
P \ 0.05 P \ 0.00008 P \ 0.001 P \ 0.00005
Nucleus accumbens
Control 6 11,274 ± 433 1,979 ± 169 206 ± 19 862 ± 41
Reserpine 0.2 6 8,892 ± 254* 1,710 ± 53* 179 ± 22 558 ± 16**
Reserpine 0.2 ? TIQ25 6 10,503 ± 6451 1,030 ± 73**?? 196 ± 14 561 ± 63**
Reserpine 0.2 ? 1MeTIQ25 6 11,521 ± 636?? 1,202 ± 44**?? 252 ± 39 581 ± 28**
F F(3/20) = 4.10 F(3/20) = 18.77 F(3/20) = 1.06 F(3/20) = 13.00
P \ 0.02 P \ 0.000005 NS P \ 0.00006
Hypothalamus
Control 6 549 ± 31 97 ± 8.6 12 ± 0.7 45 ± 3.9
Reserpine 0.2 6 324 ± 17** 91 ± 10.4 10 ± 0.9 38 ± 3.2
Reserpine 0.2 ? TIQ25 6 443 ± 36*? 50 ± 5.7**?? 19 ± 3.5*?? 39 ± 3.0
Reserpine 0.2 ? 1MeTIQ25 6 419 ± 20*1 42 ± 1.0**?? 18 ± 1.7? 25 ± 2.8**??
F F(3/20) = 7.34 F(3/20) = 14.37 F(3/20) = 4.41 F(3/20) = 6.49
P \ 0.001 P \ 0.00003 P \ 0.01 P \ 0.003
Reserpine (0.2 mg/kg i.p.) was administered chronically, once daily for 14 days. TIQ and 1MeTIQ (25 mg/kg i.p.) were administered 30 min
before each dose of reserpine (combined groups). Control group received chronically 1 % Tween 80. Animals were decapitated 120 min after the
last drug injection. The concentration of DA and its metabolites were expressed as ng/g wet tissue. The data are the mean ± SEM. The results
were analyzed by means of one-way ANOVA, followed when appropriate, by post hoc Duncan’s test
Statistical significance: * P \ 0.05, ** P \ 0.01 versus control group. ? P \ 0.05, ?? P \ 0.01 versus reserpine group
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5-Hydroxyindolacetic acid The one-way ANOVA dem-
onstrated a significant effect of treatment on the level of
5-HIAA in the tested structures: VTA (F3/20 = 11.29;
P \ 0.00012), nucleus accumbens (F3/20 = 10.15;
P \ 0.0002), and hypothalamus (F3/20 = 9.54; P \ 0.0004).
The Duncan’s post hoc test indicated that repeated treatment
of reserpine had no effect but chronic administration of TIQ
and 1MeTIQ together with reserpine produced a significant
(P \ 0.01) decrease of 5-HIAA concentration in all tested
structures (Table 5).
The Index of Serotonin Catabolism: [5-HIAA]/[5-HT]
The one-way ANOVA revealed a significant effect of
treatment on the index of serotonin catabolism [5-HIAA]/[5-
HT] in all structures: VTA (F3/20 = 29.39; P \ 0.00000),
nucleus accumbens (F3/20 = 10.65; P \ 0.0002), and
hypothalamus (F3/20 = 20.04; P \ 0.00000). The Duncan’s
post hoc test demonstrated that repeated treatment with
reserpine significantly increased serotonin metabolic index
[5-HIAA]/[5-HT] in the VTA (about 70 % of control,
P \ 0.01) and in the hypothalamus (about 60 % of control,
P \ 0.01) but did not change it in the nucleus accumbens.
TIQ and 1MeTIQ significantly antagonized the effect
evoked by reserpine in these structures and clearly decreased
the rate of serotonin metabolism in the nucleus accumbens
(from 25 to 30 % of control, respectively, P \ 0.01)
(Table 5).
Discussion
In this study, we investigated the effects of repeated
administration of a low dose of reserpine (0.2 mg/kg i.p.)
on behavioral (FST, motor function) and neurochemical
Table 3 The effect of chronic administration of TIQ and 1MeTIQ on reserpine-induced changes in the rate of DA metabolism after chronic
administration in rat brain structures
Chronic treatment (mg/kg) N [HVA]/[DA] [DOPAC]/[DA] [3-MT]/[DA]
VTA
Control 6 20 ± 2.9 29 ± 1.2 2 ± 0.3
Reserpine 0.2 6 21 ± 0.9 36 ± 1.1** 2 ± 0.1
Reserpine 0.2 ? TIQ25 6 14 ± 1.0*? 16 ± 0.8**?? 4 ± 0.3**??
Reserpine 0.2 ? 1MeTIQ25 6 10 ± 1.4**?? 14 ± 1.7**?? 4 ± 0.3**??
F F(3/20) = 8.19 F(3/20) = 71.89 F(3/
20) = 14.54
P \ 0.0009 P \ 0.0000001 P \ 0.00002
Nucleus accumbens
Control 6 8 ± 0.2 17 ± 1.4 2 ± 0.2
Reserpine 0.2 6 6 ± 0.2** 19 ± 0.5* 2 ± 0.2
Reserpine 0.2 ? TIQ25 6 5 ± 0.4**? 10 ± 0.2**?? 2 ± 0.1
Reserpine 0.2 ? 1MeTIQ25 6 5 ± 0.2**?? 10 ± 0.3**?? 2 ± 0.3
F F(3/
20) = 17.51
F(3/20) = 34.88 F(3/20) = 0.78
P \ 0.000008 P \ 0.0000001 NS
Hypothalamus
Control 6 8 ± 0.5 17 ± 0.7 2 ± 0.2
Reserpine 0.2 6 12 ± 0.8** 28 ± 1.8** 3 ± 0.2
Reserpine 0.2 ? TIQ25 6 9 ± 0.8? 11 ± 0.5**?? 5 ± 0.7**?
Reserpine 0.2 ? 1MeTIQ25 6 7 ± 0.7?? 12 ± 0.6**?? 5 ± 0.3**?
F F(3/20) = 9.02 F(3/20) = 53.42 F(3/20) = 6.56
P \ 0.0005 P \ 0.0000001 P \ 0.002
Reserpine (0.2 mg/kg i.p.) was administered chronically, once daily for 14 days. TIQ and 1MeTIQ (25 mg/kg i.p.) were administered 30 min
before each dose of reserpine (combined groups). Control group received chronically 1 % Tween 80. Animals were decapitated 120 min after
chronic drugs administration. The rate of DA total metabolism was expressed as the ratio [HVA]/[DA] 9 100; the rate of DA MAO-dependent
oxidation as the ratio: [DOPAC]/[DA] 9 100; and the rate of DA COMT-dependent O-methylation as the ratio: [3-MT]/[DA] 9 100; and
serotonin as the ratio: [5-HIAA]/[5-HT] 9 100. The indices were calculated using concentrations from individual tissue samples. The data are
the mean ± SEM. The results were analyzed by means of one-way ANOVA, followed when appropriate, by post hoc Duncan’s test
Statistical significance: * P \ 0.05, ** P \ 0.01 versus control group. ? P \ 0.05, ?? P \ 0.01 versus reserpine-treated group
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parameters, and then we studied the effect of TIQ and
1MeTIQ on reserpine-induced depression in the rat. In fact,
we observed that chronic but not acute treatment with a low
dose of reserpine induced a distinct depressive-like
behavior in the FST, motor impairment, and additionally a
significant decrease in the level of DA, NA, and serotonin
in the brain (Figs. 2, 3; Table 1).
As already well known, reserpine is an inhibitor of
VMAT2 and interferes with the storage of monoamines by
blocking the ATP-dependent uptake mechanism of the
storage organelles (Nagakura et al. 2009; Rojas-Corrales
et al. 2004). In addition to that, the oxidative catabolism of
cytosolic DA and serotonin by monoamine oxidase A and
B (MAO) is accelerated, which is followed by disappear-
ance of these neurotransmitters and formation of a cellular
oxidant hydrogen peroxide (especially in DA MAO-
dependent oxidation). This action mimics the increased
turnover of DA in the surviving dopaminergic terminals in
the course of PD (Gerlach and Riederer 1996). Interest-
ingly, the VMAT2-deficient animals showed an increased
oxidative stress, progressive loss of DA terminals, and
accumulation of a-synuclein (Caudle et al. 2007, 2008).
There are many studies showing that depression is char-
acterized by a significantly decreased antioxidant status, as
evidenced by a lowered tryptophan, tyrosine, vitamin E,
zinc concentration, and reduced glutathione, which are all
antioxidants (Maes et al. 2011; Kodydkova et al. 2009).
Recently, a new hypothesis postulating that the activation
of inflammatory and oxidative stress pathways is a key
pathophysiological factor in depression, was formulated
(Vetulani and Nalepa 2000; Maes 2008).
One of the main purposes of this study was to find out
more realistic model of depression which could be corre-
lated with neurochemical changes in monoaminergic sys-
tems for estimation antidepressant efficacy of the
investigated new compounds: TIQ and 1MeTIQ. We
applied a such small dose of reserpine (0.2 mg/kg) which
because its low concentration only partially affected a
vesicular monoamines T2 transporter, and after acute
administration did not evoke any changes in the forced
Table 4 The effect of chronic administration of TIQ and 1MeTIQ on reserpine-induced changes in the noradrenergic system after chronic
administration in the different structures of rat brain
Chronic treatment (mg/kg) N NA (ng/g wt) NM (ng/g wt) [NM]/[NA]
VTA
Control 6 606 ± 80 24 ± 4.3 4 ± 1.7
Reserpine 0.2 6 555 ± 48 16 ± 2.5* 3 ± 0.6
Reserpine 0.2 ? TIQ25 6 801 ± 22*? 30 ± 3.6?? 4 ± 0.4
Reserpine 0.2 ? 1MeTIQ25 6 763 ± 62?? 27 ± 2.0? 4 ± 0.4
F F(3/20) = 4.35 F(3/20) = 3.61 F(3/20) = 0.65
P \ 0.01 P \ 0.03 NS
Nucleus accumbens
Control 6 443 ± 48 15 ± 1.0 4 ± 0.8
Reserpine 0.2 6 233 ± 28* 9 ± 0.6* 4 ± 0.7
Reserpine 0.2 ? TIQ25 6 575 ± 133?? 16 ± 3.7? 3 ± 0.6
Reserpine 0.2 ? 1MeTIQ25 6 477 ± 37? 13 ± 1.1 3 ± 0.3
F F(3/20) = 3.37 F(3/20) = 2.13 F(3/20) = 1.48
P \ 0.03 NS NS
Hypothalamus
Control 6 1,208 ± 57 16 ± 1.0 1 ± 0.1
Reserpine 0.2 6 926 ± 71* 10 ± 0.6* 1 ± 0.1
Reserpine 0.2 ? TIQ25 6 1,133 ± 110? 67 ± 8.2**?? 6 ± 0.9**??
Reserpine 0.2 ? 1MeTIQ25 6 1,247 ± 95? 37 ± 3.0**?? 3 ± 0.2**??
F F(3/20) = 3.61 F(3/20) = 33.32 F(3/20) = 40.13
P \ 0.05 P \ 0.0000001 P \ 0.0000001
Reserpine (0.2 mg/kg i.p.) was administered chronically, once daily for 14 days. TIQ and 1MeTIQ (25 mg/kg i.p.) were administered 30 min
before each dose of reserpine (combined groups). Control group received chronically 1 % Tween 80. Animals were decapitated 120 min after
chronic drugs administration. The concentration of NA and its metabolite, normetanephrine (NM) was expressed as ng/g wet tissue. The rate of
NA metabolism was expressed as the ratio of the extraneuronal metabolite, normetanephrine to NA: [NM]/[NA] 9 100. Analogously to DA, the
indices were calculated using concentrations from individual tissue samples. The data are the mean ± SEM. The results were analyzed by means
of one-way ANOVA, followed when appropriate, by post hoc Duncan’s test
Statistical significance: * P \ 0.05, ** P \ 0.01 versus control group. ? P \ 0.05, ?? P \ 0.01 versus reserpine-treated group
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swim behavioral test as well as in the biochemical
parameters (the concentration of monoamines) in the brain.
Somehow, repeated (daily for 14 days) administration
leads to the significant ‘‘depression–like’’ syndrome in FST
with the simultaneous distinct drop of monoamine con-
centrations in the brain structures.
In the light of these observations, we can suggest that
repeated treatment with a low dose of reserpine could be a
good progressive model of depression and concomitant
abnormalities in the motivation function and, additionally,
a useful tool for testing potential new antidepressants. Our
results are also in agreement with other findings showing
that the reserpine model is characterized not only by
behavioral depression but also by impairment of mono-
amine neurotransmission in the brain (Colpaert 1987;
Gerlach and Riederer 1996; Fernandes et al. 2008, 2012).
Previous in vitro studies have shown that the investigated
compounds, TIQ and 1MeTIQ, possess free radical scav-
enging capacity and intrinsic antioxidant properties
(Antkiewicz-Michaluk et al. 2006). Several TIQs and their
congeners, including TIQ and 1MeTIQ, interfere with
MAO activity, inducing putative neuroprotection related to
the pathogenesis of PD (Naoi and Maruyama 1993). Both
compounds investigated in the present study inhibited
MAO A and MAO B activities with preferential effects on
the MAO A form (Patsenka and Antkiewicz-Michaluk
2004). These results justify the question about the physi-
ological significance of endogenous TIQs in the control of
neurotransmitter function, and prevention of neurotoxicity
related to MAO activity in the brain.
The FST measuring immobility has been shown to be an
appropriate test to evaluate antidepressant activity, as
antidepressants generally delay and decrease immobility
(Cryan et al. 2005; Murray et al. 2008; Zhao et al. 2008).
The modified FST measures the frequency of different
types of active behaviors: swimming, which is sensitive to
serotoninergic compounds, such as SSRIs, and climbing,
which is sensitive to tricyclic antidepressants and drugs
Table 5 The effect of chronic administration of TIQ and 1MeTIQ on reserpine-induced changes in the serotonin system after chronic
administration in the different structures of rat brain
Chronic treatment (mg/kg) N 5-HT (ng/g wt) 5-HIAA (ng/g wt) [5-HIAA]/[5-HT]
VTA
Control 6 430 ± 54 493 ± 61 116 ± 9.9
Reserpine 0.2 6 279 ± 19* 552 ± 37 200 ± 15.2**
Reserpine 0.2 ? TIQ25 6 377 ± 41 345 ± 49*?? 92 ± 8.5??
Reserpine 0.2 ? 1MeTIQ25 6 344 ± 38 221 ± 19**?? 67 ± 7.2**??
F F(3/20) = 2.48 F(3/20) = 11.29 F(3/20) = 29.39
NS P \ 0.0001 P \ 0.0000001
Nucleus accumbens
Control 6 551 ± 44 439 ± 22 81 ± 4.0
Reserpine 0.2 6 558 ± 34 442 ± 24 79 ± 2.9
Reserpine 0.2 ? TIQ25 6 574 ± 43 343 ± 14**?? 62 ± 5.8**??
Reserpine 0.2 ? 1MeTIQ25 6 616 ± 21 320 ± 17**?? 52 ± 3.8**??
F F(3/20) = 0.63 F(3/20) = 10.15 F(3/20) = 10.63
NS P \ 0.0002 P \ 0.0002
Hypothalamus
Control 6 746 ± 18 286 ± 7 38 ± 0.7
Reserpine 0.2 6 524 ± 32** 314 ± 15 61 ± 4.9**
Reserpine 0.2 ? TIQ25 6 658 ± 54? 210 ± 29**?? 32 ± 2.8??
Reserpine 0.2 ? 1MeTIQ25 6 667 ± 26? 207 ± 9**?? 31 ± 2.5??
F F(3/20) = 6.94 F(3/20) = 9.54 F(3/20) = 20.04
P \ 0.002 P \ 0.0004 P \ 0.000003
Reserpine (0.2 mg/kg i.p.) was administered chronically, once daily for 14 days. TIQ and 1MeTIQ (25 mg/kg i.p.) were administered 30 min
before each dose of reserpine (combined groups). Control group received chronically 1 % Tween 80. Animals were decapitated 120 min after
chronic drugs administration. The concentration of serotonin (5-HT) and its metabolite, 5-hydroxyindolacetic acid (5-HIAA) was expressed as
ng/g wet tissue. The rate of serotonin metabolism was expressed as the ratio of its metabolite, 5-HIAA to serotonin: [5-HIAA]/[5-HT]x100. The
indices were calculated using concentrations from individual tissue samples. The data are the mean ± SEM. The results were analyzed by means
of one-way ANOVA, followed when appropriate, by post hoc Duncan’s test
Statistical significance: * P \ 0.05, ** P \ 0.01 versus control group. ? P \ 0.05, ?? P \ 0.01 versus reserpine-treated group
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with selective effects on catecholamine transmission
(Cryan and Lucki 2000; Cryan et al. 2005; Detke et al.
1995). As shown by Detke et al. (1995), the increase in
climbing activity is connected with an enhanced NA sys-
tem activation.
In the present study, we observed for the first time the
antidepressant-like effect in the FST of the tetrahydroiso-
quinoline amines: TIQ and 1MeTIQ in the animal model of
depressive disorder induced by repeated administration of
reserpine. Chronic reserpine significantly increased the
immobility time in the FST, and concomitantly produced a
significant decrease in the swimming time. However, in the
locomotor activity test, both acute and repeated adminis-
tration of reserpine produced a significant depression in the
horizontal (travelled distance in cm) and vertical (rearing
time in sec.) exploratory locomotor activity of rats
(P \ 0.001) during the first 30 min after the start of the
measurement of motor activity (Fig. 3a, b). On the con-
trary, in the FST, there was a clear distinction between the
acute and chronic effects of reserpine administration,
where only chronic treatment led to the depressive-like
behavior in that test (Fig. 2). The results of these experi-
ments clearly indicate a significant dissociation between
‘‘pro-depressive’’ effects observed in the FST (inhibition of
motivation) only after repeated reserpine treatment and, in
contrast to that, depression of the locomotor activity after
both, acute and repeated administration. Taken together the
results also indicate that locomotor activity test is not
suitable for estimation ‘‘pro-depressive’’ effects in rat.
The investigated compounds, TIQ and 1MeTIQ,
administered chronically together with a low dose of
reserpine completely antagonized reserpine-produced
depression as measured by both investigated parameters:
immobility time and swimming time (Fig. 4). The behav-
ioral data obtained in the FST clearly indicate that both
compounds express antidepressant-like activity in reserpi-
nized rat. The data are in agreement with our recent papers
concerning antidepressant-like effect of TIQ and 1MeTIQ
in the FST and chronic mild stress model, which was
comparable to classic antidepressants, imipramine, and
desipramine (Wa˛sik et al. 2013; Mo _zd _zen´ et al. submitted
to the Editor 2013). Neurochemical data showed that these
effects may be connected with the activation of monoam-
inergic system (dopaminergic, serotoninergic, and norad-
renergic) in the brain. As already well known, multiple
mechanisms are responsible for the development of
depression. Monoamine neurotransmitters are involved in
the pathogenesis of depression and play an important role
in mediating the effects of antidepressants (Javaid et al.
1979; Borsini and Meli 1988). It is well documented by
clinical data that the classical antidepressants (imipramine,
desipramine) as well as SSRI activate monoaminergic
neurotransmission in the brain as reuptake inhibitors of NA
and serotonin (Grunewald et al. 1979; Javaid et al. 1979;
Borsini and Meli 1988; Borsini 1995; Cryan and Lucki
2000; Cryan et al. 2005; Detke et al. 1995).
Biochemical data demonstrated that chronic treatment
with a low dose of reserpine in contrast to acute adminis-
tration produced the depression of monoamines in the brain
structures. The concentrations of DA (in all investigated
structures), NA (in the nucleus accumbens and hypothala-
mus), and serotonin (in the VTA and hypothalamus) were
significantly lowered (Tables 2, 4, 5). In opposite, the rate
of MAO-dependent oxidation of DA and serotonin was
significantly increased (Tables 3, 5). These biochemical
effects obtained after repeated reserpine administration
were completely antagonized by chronic joint injections of
TIQ or 1MeTIQ with reserpine. Regarding the mechanism
of action of TIQs in reversing the effects of reserpine, it
was shown previously in our ex vivo experiments that both
compounds, TIQ and 1MeTIQ, shifted DA catabolism from
MAO-dependent oxidation to COMT-dependent methyla-
tion and abolished at least generation of hydroxyl radicals
via Fenton reaction (Antkiewicz-Michaluk et al. 2006).
Such MAO-dependent oxidation inhibiting effect produced
by TIQ and 1MeTIQ in reserpine-treated rats is clearly
visible both in the decline of DA and serotonin metabolites
(DOPAC and 5-HIAA, respectively) as well as in the
decrease in oxidation indices in the combined treatment
groups (Tables 2, 3, 5).
Similarly to DA and serotonin, both TIQ compounds
normalized the level of NA and its extraneuronal metabolite,
NM decreased by chronic administration of reserpine. NA
released into the synaptic cleft is catabolized by COMT to
NM by the process of COMT-dependent methylation, so this
extraneuronal metabolite is a good marker of NA release. As
it was demonstrated in the present paper, chronic reserpine
inhibited noradrenergic transmission. TIQ and 1MeTIQ
administered together with reserpine prevented the norad-
renergic depression evoked by reserpine (Table 4).
Our present data demonstrate that the investigated
compounds, TIQ and 1MeTIQ, used in the reserpine model
of depression in the rat elicited the antidepressant-like
activity in the FST. Both compounds are characterized by a
wide spectrum of actions on all monoaminergic systems in
the rat brain. Thanks to their ability to inhibit both MAO A
and MAO B activity (Patsenka and Antkiewicz-Michaluk
2004) and to scavenge free radicals (Antkiewicz-Michaluk
et al. 2006), TIQ and its close methyl derivative, 1MeTIQ
may be useful not only for the therapy of neurodegenera-
tive disease (e.g., PD) but also in the treatment of the
depression as new antidepressants. Especially, 1MeTIQ
raises hope for its application in depression as a safe drug
with proven clinically useful mechanism of action descri-
bed recently as neuroprotectant with antiaddictive potency
(Antkiewicz-Michaluk et al. 2014).
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